omidubicel-onlv (Omisirge)

Indications

• use in adults & pediatric patients >= 12 years with hematologic malignancies prior to umbilical cord blood transplantation following myeloablative conditioning

Contraindications

• sensitivity to dimethyl sulfoxide (DMSO), Dextran 40, gentamicin, human serum albumin or bovine material

Adverse effects

• infections
• infusion reactions

Mechanism of action

• anicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood
• reduces time to neutrophil recovery & incidence of infection

More general terms

• granulocyte colony-stimulating factor